GlassScriptPhysician profile
Jayne M Cole
NPI 1518929561
$6,505.86
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $664 · 2022: $2,111 · 2023: $3,186 · 2024: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,836 · Long Term Medical Supply Or Device Loan: $799 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.20 |
| Long Term Medical Supply Or Device Loan | $799.08 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,537.49 | 2021-2024 | |
| Amgen INC. | $610.07 | 2021-2023 | Kyprolis, Blincyto, Nplate |
| E.R. Squibb & Sons, L.L.C. | $428.59 | 2021-2023 | Opdivo |
| Janssen Biotech, INC. | $408.04 | 2021-2023 | Erleada |
| Pharmacyclics LLC, An Abbvie Company | $309.47 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $293.70 | 2021-2023 | Keytruda, Reblozyl, Welireg |
| Genentech USA, INC. | $292.45 | 2021-2023 | Venclexta, Tecentriq, Avastin |
| Astrazeneca Pharmaceuticals LP | $242.33 | 2021-2023 | Calquence, Lynparza |
| Celgene Corporation | $238.18 | 2022-2023 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $230.60 | 2021-2024 | |
| Astellas Pharma US INC | $158.65 | 2021-2023 | Padcev, Xtandi |
| Sirtex Medical INC | $145.70 | 2022 | |
| Lilly USA, LLC | $120.45 | 2021-2023 | Verzenio, Retevmo, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $111.14 | 2021-2023 | |
| Glaxosmithkline, LLC. | $102.33 | 2022-2023 | Zejula, Jemperli, Ojjaara |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.